Tae Hoon Lee, Kyung Su Kim, Hak Jae Kim, Chang Heon Choi, Seonghee Kang, Keun-Yong Eom, Chan Woo Wee, Yong Sang Song, Noh Hyun Park, Jae-Weon Kim, Hyun Hoon Chung, Hee Seung Kim, Maria Lee, Hyun-Cheol Kang
Cancer Res Treat. 2023;55(1):258-269. Published online August 10, 2022
Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.
Materials and Methods Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.
Results The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.
Conclusion IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.
A Mixed Methods Study to Implement the Synergy Tool and Evaluate Its Impact on Long-Term Care Residents Farinaz Havaei, Francis Kobekyaa, Andy Ma, Maura MacPhee, Wei Zhang, Megan Kaulius, Bahar Ahmadi, Sheila Boamah, Adam Easterbrook, Amy Salmon Healthcare.2023; 11(15): 2187. CrossRef
Purpose This study aimed to investigate the impact of BRCA1/2 mutational status on survival outcomes in patients with platinum-sensitive relapsed (PSR) epithelial ovarian cancer (EOC).
Materials and Methods We retrospectively identified patients who received secondary treatment for PSR EOC at our institution between January 2007 and June 2021 and who underwent BRCA1/2 gene testing by either germline or somatic methods. The association between BRCA1/2 mutational status and survival outcomes was evaluated. Both secondary cytoreductive surgery (CRS) and maintenance therapy were stratified considering real-world clinical practice.
Results Of 262 patients, 91 (34.7%) and 171 (65.3%) were assigned to BRCA1/2 mutation and wild-type groups, respectively. The two groups had similar proportions of patients undergoing secondary CRS (26.4% vs. 32.7%, p=0.286) and maintenance therapy (54.9% vs. 46.2%, p=0.178). Overall, no differences in progression-free survival (PFS; median, 19.7 vs. 15.1 months, p=0.120) and overall survival (OS; p=0.400) were observed between the two groups. In multivariate analyses, BRCA1/2 mutational status was not associated with PFS (adjusted hazard ratio, 0.816; 95% confidence interval, 0.596 to 1.119; p=0.207). BRCA1/2 mutational status did not affect PFS among patients who underwent secondary CRS (n=80) and among those who did not (n=182) (p=0.074 and p=0.222, respectively). PFS did not differ in the BRCA1/2 mutational status among the patients who received bevacizumab maintenance (n=90, p=0.992).
Conclusion In this real-world evidence study, BRCA1/2 mutational status itself was not associated with PFS and OS in PSR EOC, which was consistent with whether secondary CRS or not and with bevacizumab maintenance.
Purpose This study aimed to identify patients who would benefit from third and subsequent lines of chemotherapy in recurrent epithelial ovarian cancer (EOC).
Materials and Methods Recurrent EOC patients who received third, fourth, or fifth-line palliative chemotherapy were retrospectively analyzed. Patients’ survival outcomes were assessed according to chemotherapy lines. Based on the best objective response, patients were divided into good-response (stable disease or better) and poor response (progressive disease or those who died before response assessment) groups. Survival outcomes were compared between the two groups, and factors associated with chemotherapy responses were investigated.
Results A total of 189 patients were evaluated. Ninety-four and 95 patients were identified as good and poor response group respectively, during the study period of 2008 to 2021. The poor response group showed significantly worse progression-free survival (median, 2.1 months vs. 9.7 months; p < 0.001) and overall survival (median, 5.0 months vs. 22.9 months; p < 0.001) compared with the good response group. In multivariate analysis adjusting for clinicopathologic factors, short treatment-free interval (TFI) (hazard ratio [HR], 5.557; 95% confidence interval [CI], 2.403 to 12.850), platinum-resistant EOC (HR, 2.367; 95% CI, 1.017 to 5.510), and non-serous/endometrioid histologic type (HR, 5.045; 95% CI, 1.152 to 22.088) were identified as independent risk factors for poor response. There was no difference in serious adverse events between good and poor response groups (p=0.167).
Conclusion Third and subsequent lines of chemotherapy could be carefully considered for palliative purposes in recurrent EOC patients with serous or endometrioid histology, initial platinum sensitivity, and long TFIs from the previous chemotherapy regimen.
Citations
Citations to this article as recorded by
CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression Chunyan Huang, Li Qin, Sailan Chen, Qin Huang Anti-Cancer Drugs.2022;[Epub] CrossRef
Purpose
This study aimed to present a single institutional experience with BRCA1/2 gene tests and the effects of pathogenic mutations in epithelial peritoneal, ovarian, and fallopian tube cancer (POFTC) on survival outcomes.
Materials and Methods
We identified patients with epithelial POFTCs who underwent BRCA1/2 gene testing by either germline or somatic methods between March 2007 and March 2020. Based on the BRCA1/2 test results, patients were divided into BRCA mutation and wild-type groups, followed by comparisons of clinicopathologic characteristics and survival outcomes after primary treatment.
Results
The annual number of POFTC patients who received BRCA1/2 gene tests increased gradually. In total, 511 patients were included and BRCA1/2 mutations were observed in 143 (28.0%). Among 57 patients who received both germline and somatic tests, three (5.3%) showed discordant results from the two tests. Overall, no differences in progression-free survival (PFS; p=0.467) and overall survival (p=0.641) were observed between the BRCA mutation and wild-type groups; however, multivariate analyses identified BRCA1/2 mutation as an independent favorable prognostic factor for PFS (adjusted hazard ratio [aHR], 0.765; 95% confidence interval [CI], 0.593 to 0.987; p=0.040). In 389 patients with International Federation of Gynecology and Obstetrics stage III-IV, different results were shown depending on primary treatment strategy: while BRCA1/2 mutation significantly improved PFS in the subgroup of neoadjuvant chemotherapy (aHR, 0.619; 95% CI, 0.385 to 0.995; p=0.048), it did not affect patient PFS in the subgroup of primary debulking surgery (aHR, 0.759; 95% CI, 0.530 to 1.089; p=0.135).
Conclusion BRCA1/2 mutations are frequently observed in patients with epithelial POFTCs, and such patients showed better PFS than did those harboring wild-type BRCA1/2.
Citations
Citations to this article as recorded by
Overview of Molecular Diagnostics in Irish Clinical Oncology Tyler Medina, Seán O. Hynes, Maeve Lowery, Paddy Gillespie, Walter Kolch, Cathal Seoighe HRB Open Research.2024; 7: 16. CrossRef
Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea Se Ik Kim, Hyeong In Ha, Kyung Jin Eoh, Jiwon Lim, Young-Joo Won, Myong Cheol Lim Frontiers in Oncology.2022;[Epub] CrossRef
Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers Zongbi Yi, Min Chen, Shaoxing Sun, Chunxu Yang, Zijie Mei, Hui Yang, Qingming Xiang, Hui Qiu Cancer Innovation.2022; 1(3): 220. CrossRef
Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song
Cancer Res Treat. 2019;51(3):1144-1155. Published online November 20, 2018
Purpose
Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC.
Materials and Methods
We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinico-pathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied.
Results
The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively.
Conclusion
We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.
Citations
Citations to this article as recorded by
Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer Jianfeng Zheng, Shan Jiang, Xuefen Lin, Huihui Wang, Li Liu, Xintong Cai, Yang Sun BMC Women's Health.2024;[Epub] CrossRef
Peripheral and tumor‐infiltrating immune cells are correlated with patient outcomes in ovarian cancer Weiwei Zhang, Yawen Ling, Zhidong Li, Xingchen Peng, Yazhou Ren Cancer Medicine.2023; 12(8): 10045. CrossRef
Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods Seung Mi Lee, Suhyun Hwangbo, Errol R. Norwitz, Ja Nam Koo, Ig Hwan Oh, Eun Saem Choi, Young Mi Jung, Sun Min Kim, Byoung Jae Kim, Sang Youn Kim, Gyoung Min Kim, Won Kim, Sae Kyung Joo, Sue Shin, Chan-Wook Park, Taesung Park, Joong Shin Park Clinical and Molecular Hepatology.2022; 28(1): 105. CrossRef
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives Stanislas Quesada, Michel Fabbro, Jérôme Solassol Cancers.2022; 14(4): 1098. CrossRef
Construction and validation of a transcription factors-based prognostic signature for ovarian cancer Qingyuan Cheng, Liman Li, Mingxia Yu Journal of Ovarian Research.2022;[Epub] CrossRef
Predicting preterm birth through vaginal microbiota, cervical length, and WBC using a machine learning model Sunwha Park, Jeongsup Moon, Nayeon Kang, Young-Han Kim, Young-Ah You, Eunjin Kwon, AbuZar Ansari, Young Min Hur, Taesung Park, Young Ju Kim Frontiers in Microbiology.2022;[Epub] CrossRef
Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma Jiayi Li, Dongyan Cao Frontiers in Oncology.2022;[Epub] CrossRef
Recent Advances and Future Directions of Diagnostic and Prognostic Prediction Models in Ovarian Cancer Judan Zeng, Wenjiao Cao, Lihua Wang Journal of Shanghai Jiaotong University (Science).2021; 26(1): 10. CrossRef
Sphingolipids as multifaceted mediators in ovarian cancer MelissaR Pitman, Martin K. Oehler, Stuart M. Pitson Cellular Signalling.2021; 81: 109949. CrossRef
Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition Jiani Yang, Jun Ma, Yue Jin, Shanshan Cheng, Shan Huang, Nan Zhang, Yu Wang Scientific Reports.2021;[Epub] CrossRef
Prediction Models for the Clinical Severity of Patients With COVID-19 in Korea: Retrospective Multicenter Cohort Study Bumjo Oh, Suhyun Hwangbo, Taeyeong Jung, Kyungha Min, Chanhee Lee, Catherine Apio, Hyejin Lee, Seungyeoun Lee, Min Kyong Moon, Shin-Woo Kim, Taesung Park Journal of Medical Internet Research.2021; 23(4): e25852. CrossRef
Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song Cancers.2021; 13(8): 1875. CrossRef
M2 Macrophage-Based Prognostic Nomogram for Gastric Cancer After Surgical Resection Jianwen Hu, Yongchen Ma, Ju Ma, Yanpeng Yang, Yingze Ning, Jing Zhu, Pengyuan Wang, Guowei Chen, Yucun Liu Frontiers in Oncology.2021;[Epub] CrossRef
Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization Ji-Bin Liu, Kai-Jian Chu, Chang-Chun Ling, Ting-Miao Wu, Hui-Min Wang, Yi Shi, Zhi-Zhen Li, Jing-Han Wang, Zhi-Jun Wu, Xiao-Qing Jiang, Gao-Ren Wang, Yu-Shui Ma, Da Fu Current Problems in Cancer.2020; 44(6): 100612. CrossRef
Can we predict who lives long with ovarian cancer? Michael A. Bookman Cancer.2019; 125(S24): 4578. CrossRef
Maria Lee, Yumi Lee, Kidong Kim, Eun Young Park, Myong Cheol Lim, Jung-Sup Kim, Hee Seung Kim, Yong-Beom Kim, Yong-Man Kim, Jungnam Joo, Sang Yoon Park, Chel Hun Choi, Jae-Hoon Kim
Cancer Res Treat. 2019;51(1):112-118. Published online March 7, 2018
Purpose
The purpose of this study was to develop Korean versions of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item (NTX-4), evaluating their reliability and reproducibility.
Materials and Methods
In converting NFOSI-18 and NTX-4, the following steps were performed: forward translation, backward translation, expert review, pretest of preliminary format, and finalization of Korean versions (K-NFOSI-18 and K-NTX-4). Patients were enrolled from six institutions where each had completed chemotherapy for ovarian, tubal, or peritoneal cancer at least 1 month earlier. In addition to demographics obtained by questionnaire, all subjects were assessed via K-NFOSI-18, K-NTX-4, and a Korean version of the EuroQoL-5 Dimension. Internal structural validity and reliability were evaluated using item internal consistency, item discriminant validity, and Cronbach's α. To evaluate test-retest reliability, K-NFOSI-18 and K-NTX-4 were readministered after 7-21 days, and intraclass correlation coefficients (ICCs) were calculated.
Results
Of the 250 women enrolled during the 3-month recruitment period, 13 withdrew or did not respond, leaving 237 (94.8%) for the analyses. Mean patient age was 54.3±10.8 years. Re-testing was performed in 190 patients (80.2%). The total K-NFOSI-18 and K-NTX-4 scores were 49 (range, 20 to 72) and 9 (range, 0 to 16), respectively, with high reliability (Cronbach's α=0.84 and 0.89, respectively) and reproducibility (ICC=0.77 and 0.84, respectively) achieved in retesting.
Conclusion
Both NFOSI-18 and NTX-4 were successfully developed in Korean with minimal modification. Each Korean version showed high internal consistency and reproducibility.
Citations
Citations to this article as recorded by
Peripheral Neuropathy Instruments for Individuals with Cancer: A COSMIN-Based Systematic Review of Measurement Properties Silvia Belloni, Arianna Magon, Chiara Giacon, Francesca Savioni, Gianluca Conte, Rosario Caruso, Cristina Arrigoni Current Oncology.2024; 31(12): 7828. CrossRef
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review Charlotte L Moss, Teresa Guerrero-Urbano, Ingrid White, Benjamin Taylor, Rebecca Kristeleit, Ana Montes, Louis Fox, Katharina Beyer, Monika Sztankay, Maria M Ratti, Elena S Sisca, Alexandra Derevianko, Steven MacLennan, Nicholas Wood, Lisa M Wintner, Miek Future Oncology.2023; 19(9): 663. CrossRef
Validity and Reliability of the Turkish Version of National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18) and Neurotoxicity-4 (NTX-4) for Patients with Advanced Ovarian Cancer Husnu Tore Yavuzsen, Sukriye Cansu Gulteki̇n, Karya Polat, Murat Keser, Zeynep Gulsum Guc, Merve Keskinkilic, Tugba Yavuzsen, Didem Karadibak, Sourav Panja European Journal of Cancer Care.2023; 2023: 1. CrossRef
Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use Tiffany Li, Susanna B. Park, Eva Battaglini, Madeleine T. King, Matthew C. Kiernan, David Goldstein, Claudia Rutherford Quality of Life Research.2022; 31(11): 3091. CrossRef
Influence of chemotherapy on postural control and quality of life in women with gynaecological cancer: a protocol of a prospective observational study Aline Reinmann, Anne-Violette Bruyneel, Joseph Gligorov, Serge Mesure, Christophe Combescure, Thibaud Koessler, Alexandre Bodmer BMJ Open.2022; 12(9): e061664. CrossRef
Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Tae-Yong Kim, Yu Jung Kim, Sae-Won Han, Eunyoung Kang, Eun-Kyu Kim, Kidong Kim, Jae Hong No, Wonshik Han, Dong-Young Noh, Maria Lee, Hee Seung Kim, Seock-Ah Im, Jee Hyun Kim
Cancer Res Treat. 2017;49(4):1153-1163. Published online February 27, 2017
Purpose
Although combining aromatase inhibitors (AI) with gonadotropin-releasing hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as effective as bilateral salpingo-oophorectomy (BSO).
Materials and Methods
We retrospectively analyzed data of 66 premenopausal patients with hormone receptor– positive, human epidermal growth factor receptor 2–negative recurrent and metastatic breast cancer who had been treated with AIs in combination with GnRHa or BSO between 2002 and 2015.
Results
The median patient age was 44 years. Overall, 24 (36%) received BSO and 42 (64%) received GnRHa. The clinical benefit rate was higher in the BSO group than in the GnRHa group (88% vs. 69%, p=0.092). Median progression-free survival (PFS) was longer in the BSO group, although statistical significance was not reached (17.2 months vs. 13.3 months, p=0.245). When propensity score matching was performed, the median PFS was 17.2 months for the BSO group and 8.2 months for the GnRHa group (p=0.137). Multivariate analyses revealed that the luminal B subtype (hazard ratio, 1.67; 95% confidence interval [CI], 1.08 to 2.60; p=0.022) and later-line treatment (≥ third line vs. first line; hazard ratio, 3.24; 95% CI, 1.59 to 6.59; p=0.001) were independent predictive factors for a shorter PFS. Incomplete ovarian suppression was observed in a subset of GnRHa-treated patients whose disease showed progression, with E2 levels higher than 21 pg/mL.
Conclusion
Both BSO and GnRHa were found to be effective in our AI-treated premenopausal metastatic breast cancer patient cohort. However, further studies in larger populations are needed to determine if BSO is superior to GnRHa.
Citations
Citations to this article as recorded by
Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists Jinna Lin, Shuqi Zheng, Qiang Liu Cancer Treatment Reviews.2025; 133: 102879. CrossRef
Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study Yifei Chen, Ruyan Zhang, Ying Yan, Huiping Li, Guohong Song Breast Cancer Research and Treatment.2024; 206(3): 543. CrossRef
Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects Fatima Khan, Kristin Rojas, Matthew Schlumbrecht, Patricia Jeudin Current Oncology.2023; 30(2): 1794. CrossRef
Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study Dwi Ris Andriyanto, Prihantono, Salman Ardi Syamsu, Muhammad Ihwan Kusuma, Joko Hendarto, Indra, Nilam Smaradania, Elridho Sampepajung, Asrul Mappiwali, Muhammad Faruk Annals of Medicine & Surgery.2022;[Epub] CrossRef
Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer—A Single-Center Analysis Joana Correia Oliveira, Filipa Costa Sousa, Inês Gante, Margarida Figueiredo Dias Medicina.2021; 57(4): 385. CrossRef
Long-term effect of repeated deslorelin acetate treatment in bitches for reproduction control Brändli SP, Palm J, Kowalewski MP, Reichler IM Theriogenology.2021; 173: 73. CrossRef
Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review Gebra Cuyún Carter, Maitreyee Mohanty, Keri Stenger, Claudia Morato Guimaraes, Shivaprasad Singuru, Pradeep Basa, Sheena Singh, Vanita Tongbram, Sherko Kuemmel, Valentina Guarneri, Sara M Tolaney Cancer Management and Research.2021; Volume 13: 6537. CrossRef
Oophorectomy as a Hormonal Ablation Therapy in Metastatic and Recurrent Breast Cancer: Current Indications and Results Islam H. Metwally, Omar Hamdy, Saleh S. Elbalka, Mohamed Elbadrawy, Dina M. Elsaid Indian Journal of Surgical Oncology.2019; 10(3): 542. CrossRef
Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances Aditya Bardia, Sara Hurvitz Clinical Cancer Research.2018; 24(21): 5206. CrossRef
Purpose
We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC).
Materials and Methods
The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes.
Results
Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted noncomplete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers.
Conclusion
CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.
Citations
Citations to this article as recorded by
Ovarian clear cell carcinoma: open questions on the management and treatment algorithm Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli The Oncologist.2025;[Epub] CrossRef
A clinicoradiological model based on clinical and CT features for preoperative prediction of histological classification in patients with epithelial ovarian cancers: a two-center study Jiaojiao Li, Wenjiang Wang, Bin Zhang, Xiaolong Zhu, Di Liu, Chuangui Li, Fang Wang, Shujun Cui, Zhaoxiang Ye Abdominal Radiology.2025;[Epub] CrossRef
Correlation between pre-operative platelets count and serum cancer antigen-125 level in epithelial ovarian carcer Justina Omoikhefe Alegbeleye, Celestine Osita John Indian Journal of Obstetrics and Gynecology Research.2024; 11(1): 17. CrossRef
Trends in survival of ovarian clear cell carcinoma patients from 2000 to 2015 Bing-Qian Tian, Shu-Wen Wang, Jing-Ying Xu, San-Gang Wu, Juan Zhou Frontiers in Oncology.2024;[Epub] CrossRef
Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line Jaime Espinós, José Manuel Aramendía, Antonio González-Martín, Marta Santisteban, Luisa Sánchez, Ángel Vizcay, José Ángel Mínguez, Juan Luis Alcázar Clinical and Translational Oncology.2024; 26(12): 3211. CrossRef
The prognostic and clinical value of neutrophil-to-lymphocyte ratio (NLR) in ovarian cancer: A systematic review and meta-analysis Zihan Zhang, Jinghe Lang Journal of Medical Biochemistry.2024; 43(4): 323. CrossRef
Evaluation of inflammatory mediators as predictors ofprogression-free time (PFS) in patients with ovarian cancer(HGSOC) before and during treatment Urszula Rychlik, Wiktor Szatkowski, Andrzej Kałamacki, Aneta Janicka, Karolina Górniak, Karolina Górniak, Paweł Blecharz Diagnostyka Laboratoryjna.2024; 60(4): 231. CrossRef
Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors Ke Huang, Shengjie Xu, Jiatong Wang, Lili Ge, Juan Xu, Xuemei Jia Journal of Ovarian Research.2023;[Epub] CrossRef
Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR Chuan-long Zhang, Xiao-chen Jiang, Yi Li, Xue Pan, Meng-qi Gao, Yan Chen, Bo Pang Journal of Ovarian Research.2023;[Epub] CrossRef
Trends in Systemic Inflammatory Reaction (SIR) during Paclitaxel and Carboplatin Chemotherapy in Women Suffering from Epithelial Ovarian Cancer Michal Mleko, Elzbieta Pluta, Kazimierz Pitynski, Maciej Bodzek, Andrzej Kałamacki, Dorota Kiprian, Tomasz Banas Cancers.2023; 15(14): 3607. CrossRef
Research Progress of the Relationship between Peripheral Blood Indexes and the Diagnosis, Treatment and Prognosis of Ovarian Cancer 洁 严 Advances in Clinical Medicine.2023; 13(11): 17362. CrossRef
Diagnostic significance of neutrophil to lymphocyte ratio in endometriosis: a systematic review and meta-analysis Fatemeh Tabatabaei, Hossein Tahernia, Arshin Ghaedi, Aida Bazrgar, Shokoufeh Khanzadeh BMC Women's Health.2023;[Epub] CrossRef
Comparison of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio levels in ovarian cyst among epithelial ovarian cancer patients at RSUP H. Adam Malik Medan, Indonesia Mega Sari Dewi, Roy Yustin Simanjuntak, Letta Sari Lintang, Muhammad Fahdhy, Deri Edianto, Makmur Sitepu Majalah Obstetri & Ginekologi.2023; 31(3): 117. CrossRef
The role of IL-6/JAK2/STAT3 signaling pathway in cancers Bei Huang, Xiaoling Lang, Xihong Li Frontiers in Oncology.2022;[Epub] CrossRef
Evaluation of CA-125 Biomarker in Acute Appendicitis Patients: Correlation with Clinical Symptoms and Lab Results Mojtaba Ahmadinejad, Seyed A. Hashemi, Alireza Shirzadi, Ali Soltanian, Jafar Ashrafi, Kourosh Kabir, Mahla Alizadeh The Open Public Health Journal.2021; 14(1): 162. CrossRef
The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain Na Wang, Cuiping Li, Yujie Yang, Yu Guan, Fengjiao Wang, Yan Wang, Wei Zhao World Neurosurgery.2021; 149: 502. CrossRef
Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies – State of the Art Michal Mleko, Kazimierz Pitynski, Elzbieta Pluta, Aleksandra Czerw, Katarzyna Sygit, Beata Karakiewicz, Tomasz Banas Cancer Management and Research.2021; Volume 13: 5491. CrossRef
The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis Ting Chen, Jia‐Ling Wei, Ting Leng, Fei Gao, Shun‐yu Hou Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer Carolina Maria Sassu, Innocenza Palaia, Serena Maria Boccia, Giuseppe Caruso, Giorgia Perniola, Federica Tomao, Violante Di Donato, Angela Musella, Ludovico Muzii International Journal of Molecular Sciences.2021; 22(24): 13650. CrossRef
Prognostic significance of preoperative circulating FAR and FCI scores in patients with ovarian cancer Huige Wang, Yanjun Shen, Xiaoyan Ding, Yongfen Ding, Ling Cheng, Juan Lai Clinica Chimica Acta.2020; 509: 252. CrossRef
Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications Wei Chen, Siyuan Zhong, Boer Shan, Shuling Zhou, Xiaohua Wu, Huijuan Yang, Shuang Ye Journal of Ovarian Research.2020;[Epub] CrossRef
Preoperative neutrophil-to-lymphocyte ratio predicts 30 day postoperative morbidity and survival after primary surgery for ovarian cancer Julie My Van Nguyen, Sarah Elizabeth Ferguson, Marcus Q Bernardini, Taymaa May, Stephane Laframboise, Liat Hogen, Geneviève Bouchard-Fortier International Journal of Gynecological Cancer.2020; 30(9): 1378. CrossRef
Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management Aeran Seol, Se Ik Kim, Yong Sang Song Sports Medicine and Health Science.2020; 2(4): 202. CrossRef
Associations between Blood Cell Profiles and Primary Open-Angle Glaucoma: A Retrospective Case-Control Study Binghua Tang, Shengjie Li, Jianping Han, Wenjun Cao, Xinghuai Sun Ophthalmic Research.2020; 63(4): 413. CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma Kosuke Yoshida, Nobuhisa Yoshikawa, Akira Shirakawa, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama, Fumitaka Kikkawa Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer Jie-Ping Chen, Qi-Dan Huang, Ting Wan, Hua Tu, Hai-Feng Gu, Jun-Ya Cao, Ji-Hong Liu Journal of Ovarian Research.2019;[Epub] CrossRef
Pretreatment platelet‐to‐lymphocyte ratio is associated with the response to first‐line chemotherapy and survival in patients with metastatic gastric cancer Jin Wang, Jinglei Qu, Zhi Li, Xiaofang Che, Jing Liu, Yuee Teng, Bo Jin, Mingfang Zhao, Yunpeng Liu, Xiujuan Qu Journal of Clinical Laboratory Analysis.2018;[Epub] CrossRef
Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review Naoko Komura, Seiji Mabuchi, Eriko Yokoi, Katsumi Kozasa, Hiromasa Kuroda, Tomoyuki Sasano, Yuri Matsumoto, Tadashi Kimura International Journal of Clinical Oncology.2018; 23(1): 104. CrossRef
Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies Zhe Zhao, Xinrui Zhao, Jingjing Lu, Jing Xue, Peishu Liu, Hongluan Mao Archives of Gynecology and Obstetrics.2018; 297(4): 849. CrossRef
The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis Joanna L. Sylman, Annachiara Mitrugno, Michelle Atallah, Garth W. Tormoen, Joseph J. Shatzel, Samuel Tassi Yunga, Todd H. Wagner, John T. Leppert, Parag Mallick, Owen J. T. McCarty Frontiers in Oncology.2018;[Epub] CrossRef
Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer Katarzyna Bednarska, Ewa Król, Ewa Głowacka, Hanna Romanowicz, Krzysztof Szyłło, Magdalena Klink, Zofia Sułowska, Marek Nowak Medicine.2018; 97(12): e0180. CrossRef
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24) Alberto Farolfi, Micaela Petrone, Emanuela Scarpi, Valentina Gallà, Filippo Greco, Claudia Casanova, Lucia Longo, Gennaro Cormio, Michele Orditura, Alessandra Bologna, Laura Zavallone, Jole Ventriglia, Elisena Franzese, Vera Loizzi, Donatella Giardina, Ev Targeted Oncology.2018; 13(4): 469. CrossRef
Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma Jun Zhu, Long Jiang, Hao Wen, Rui Bi, Xiaohua Wu, Xingzhu Ju International Journal of Gynecological Cancer.2018; 28(6): 1108. CrossRef
Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis Gaowen Chen, Lin Zhu, Yulu Yang, Yusheng Long, Xiangyuan Li, Yifeng Wang Technology in Cancer Research & Treatment.2018;[Epub] CrossRef
Preoperative multiplication of neutrophil and monocyte counts as a prognostic factor in epithelial ovarian cancer E Sun Paik, Minhee Shim, Hyun Jin Choi, Yoo-Young Lee, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae Cancer Biomarkers.2017; 17(4): 419. CrossRef
Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis Josee-Lyne Ethier, Danielle N Desautels, Arnoud J Templeton, Amit Oza, Eitan Amir, Stephanie Lheureux Gynecologic Oncology.2017; 145(3): 584. CrossRef
The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer Anastasia Prodromidou, Panagiotis Andreakos, Charalampos Kazakos, Dimitrios Eftimios Vlachos, Despina Perrea, Vasilios Pergialiotis Inflammation Research.2017; 66(6): 467. CrossRef
The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma Lihong Cong, Likuan Hu International Immunopharmacology.2017; 46: 75. CrossRef
Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis Yanlin Luo, Hee Seung Kim, Miseon Kim, Maria Lee, Yong Sang Song Journal of Gynecologic Oncology.2017;[Epub] CrossRef
Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway Boyun Kim, Hee Seung Kim, Soochi Kim, Guy Haegeman, Benjamin K. Tsang, Danny N. Dhanasekaran, Yong Sang Song Cancer Research and Treatment.2017; 49(2): 338. CrossRef
Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma Hongwei Zhang, Jiaqi Lu, Yingying Lu, Jiayi Zhou, Zehua Wang, Haiou Liu, Congjian Xu, Renato Franco PLOS ONE.2017; 12(5): e0177520. CrossRef
Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis Shubo Chen, Liu Zhang, Guangyue Yan, Sijin Cheng, Abdel Hamid Fathy, Nana Yan, Yongzhao Zhao BioMed Research International.2017; 2017: 1. CrossRef
Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients Quan Zhou, Li Hong, Man-Zhen Zuo, Ze He Oncotarget.2017; 8(40): 68938. CrossRef
Predictive value of systematic inflammatory response biomarkers (NLR, LMR, PLR) in patients with ovarian cancer. Urszula Rychlik, Ewa Wójcik, Jadwiga Tarapacz, Katarzyna Brandys, Zofia Stasik, Beata Kala, Jan K. Kulpa, Wiktor Szatkowski, Paweł Blecharz, Jerzy Jakubowicz Diagnostyka Laboratoryjna.2017; 53(3): 139. CrossRef
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy Yi Miao, Qin Yan, Shuangdi Li, Bilan Li, Youji Feng Cancer Biomarkers.2016; 17(1): 33. CrossRef
Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma Jia-Zhu Wu, Tian Tian, Ying Huang, Jin-Hua Liang, Yi Miao, Li Wang, Ji Xu, Xiao-Yan Qu, Lei Fan, Jian-Yong Li, Wei Xu Cancer Biomarkers.2016; 17(2): 205. CrossRef
The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study Huimin Bai, Guisha Sha, Meizhu Xiao, Huiqiao Gao, Dongyan Cao, Jiaxin Yang, Jie Chen, Yue Wang, Zhenyu Zhang, Keng Shen Oncotarget.2016; 7(13): 15566. CrossRef
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer Ghazala Khan, Suzanne E. Brooks, Ken I. Mills, Barbara-Ann Guinn Biomarkers in Cancer.2015; 7: BIC.S28378. CrossRef